



FDA NMPA CLEARED CE USA CPT Reimbursement Code

## Precision patient care.


# Improve blood pressure management with central aortic pressure and digital vascular biomarkers.

Successful treatment of hypertensive disorders involves measuring and interpreting digital vascular biomarkers that can signal risk factors for cardiovascular diseases. The SphygmoCor® XCEL platform is the physician's diagnostic tool for individualizing care that complements conventional brachial pressure monitoring to enhance precision in hypertension management decisions.

ATCOR focuses on improving the lives of patients to achieve optimum cardiovascular health through precision monitoring of central blood pressure and digital biomarkers.

### SphygmoCor Digital Vascular Biomarkers

SphygmoCor offers noninvasive assessment of the central arterial pressure waveform using a standard brachial cuff to provide central pressures and indices of arterial stiffness. Our patented technology provides accurate central aortic pressure that directly impact the heart, brain, and kidneys.



SphygmoCor technology developed for home and office use



Seamless integration into current clinical practices




Reimbursable using US CPT Code 93050

## Optimize Pharmacotherapy with SphygmoCor

Measurements of central arterial pressures can be incorporated into today's approaches of hypertension management utilizing currently available non-invasive devices that measure central pressures concurrent with brachial blood pressures.

### Incorporation of SphygmoCor into the treatment paradigm for hypertension offers advantages:

1. Concurrent elevation in brachial and central pressures confirms that hypertension is present so that initiation of medication is more likely to be the correct decision for an individual patient.
2. Elevated brachial pressure but normal central pressures suggests that white coat hypertension is present and may therefore avoid initiation of medication.
3. Borderline high peripheral pressures but normal central pressures indicates that increased treatment may not be needed.
4. Normal peripheral and low central pressures indicates that reduction of medication should be considered.



## SphygmoCor by the Numbers



All **"Top 20 Hospitals"** use SphygmoCor technology to measure central blood pressure (cBP)



**1,400+** papers have been published in leading peer-reviewed journals like *Hypertension*, *Journal of Clinical Hypertension*, and the *Journal of the American College of Cardiology*



**8 out of Top 10 Pharma companies** have used SphygmoCor technology in their clinical trials



Over **11,000 patients** have been tested with SphygmoCor technology in pharmaceutical trials

Learn more about how **SphygmoCor** can help your patients and improve your practice: [info@atcormedical.com](mailto:info@atcormedical.com)

[www.atcormedical.com](http://www.atcormedical.com)

**ATCOR**   
A CARDIEX COMPANY